Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4876714 | 0.99 | CHRM3 (0.51) | CHRM3KMT2AMEN1ALDH1A1HTT | |
| SCHEMBL4641579 | 0.83 | CHRM3 (0.51) | CHRM3KMT2AMEN1ALDH1A1SIGMAR1 | |
| SCHEMBL5106067 | 0.80 | CHRM3 (0.53) | CHRM3KMT2AMEN1ALDH1A1HTT | |
| SCHEMBL4620926 | 0.78 | CHRM3 (0.57) | CHRM3HTT | |
| SCHEMBL5948523 | 0.78 | CHRM2 (0.54) | CHRM3 | |
| SCHEMBL5948525 | 0.78 | CHRM2 (0.54) | CHRM3 | |
| SCHEMBL4179648 | 0.77 | CHRM3 (0.53) | CHRM3KMT2AMEN1ALDH1A1HTT | |
| SCHEMBL3222150 | 0.77 | HTT (0.53) | CHRM3KMT2AMEN1ALDH1A1HTT | |
| SCHEMBL3214986 | 0.77 | HTT (0.53) | CHRM3KMT2AMEN1ALDH1A1HTT | |
| Hydrochloric Acid SCHEMBL9195371 | 0.75 | CHRM3 (0.57) | CHRM3KMT2AMEN1ALDH1A1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319043-A1 | 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319043-A1 | 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists | CHRM3, CHRM5, CHRM2 | CHRM3 1/4885KMT2A 3710/4885MEN1 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.